UNSPSC 51111703: Daunorubicin citrate

This classification denotes an anthracycline antibiotic with the molecular formula C27H29NO10.C6H8O7, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5L84T2Z6NP. European Medicines Agency schedules daunorubicin citrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB22734. The term daunorubicin citrate is a U.S. FDA designation. Most nations schedule daunorubicin citrate under HS 29419000 and SITC 54139. As of Q4 2014, DAUNORUBICIN CITRATE remains the US FDA Preferred Term for this commodity.

Daunorubicin citrate bears US NLM identifiers UMLS ID C1289972 and NCI Concept Code C47471. SMILES: CC1C(C(CC(O1)OC2CC(CC3=C(C4=C(C(=C23)O)C(=O)C5=C(C4=O)C=CC=C5OC)O)(C(=O)C)O)N)O.C(C(=O)O)C(CC(=O)O)(C(=O)O)O.

UNSPSC 51111703 Daunorubicin citrate, a Commodity code, represents a chemotherapy agent that state and local health systems and correctional facilities procure for oncology treatment programs. Daunorubicin citrate is an anthracycline chemotherapy drug used in the treatment of acute leukemias and certain lymphomas, and it appears in state and local procurement primarily through health department purchasing, hospital system acquisitions, and department-of-corrections medical supply contracts. The code spans pharmaceutical procurement channels that include both direct purchase and group purchasing organization (GPO) cooperative agreements, which many state health agencies and county hospital systems leverage to manage costs and standardize sourcing across multiple facilities.

The source provided contains no recent state and local contract opportunities under this code. Without documented recent solicitations, geographic spread and issuer concentration cannot be characterized from current procurement activity.